hVIVO PLC
LSE:HVO

Watchlist Manager
hVIVO PLC Logo
hVIVO PLC
LSE:HVO
Watchlist
Price: 22 GBX -3.93% Market Closed
Market Cap: 149.7m GBX
Have any thoughts about
hVIVO PLC?
Write Note

hVIVO PLC
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

hVIVO PLC
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
hVIVO PLC
LSE:HVO
Total Equity
ÂŁ38.5m
CAGR 3-Years
21%
CAGR 5-Years
38%
CAGR 10-Years
39%
Oxford Nanopore Technologies PLC
LSE:ONT
Total Equity
ÂŁ643.9m
CAGR 3-Years
51%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Total Equity
ÂŁ31.4m
CAGR 3-Years
-8%
CAGR 5-Years
64%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Total Equity
ÂŁ1.5m
CAGR 3-Years
-34%
CAGR 5-Years
N/A
CAGR 10-Years
-18%
Ergomed PLC
LSE:ERGO
Total Equity
ÂŁ90.9m
CAGR 3-Years
28%
CAGR 5-Years
22%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Total Equity
ÂŁ24.6m
CAGR 3-Years
9%
CAGR 5-Years
14%
CAGR 10-Years
N/A
No Stocks Found

hVIVO PLC
Glance View

Market Cap
149.7m GBX
Industry
Life Sciences Tools & Services

hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

HVO Intrinsic Value
26.83 GBX
Undervaluation 18%
Intrinsic Value
Price

See Also

What is hVIVO PLC's Total Equity?
Total Equity
38.5m GBP

Based on the financial report for Jun 30, 2024, hVIVO PLC's Total Equity amounts to 38.5m GBP.

What is hVIVO PLC's Total Equity growth rate?
Total Equity CAGR 10Y
39%

Over the last year, the Total Equity growth was 78%. The average annual Total Equity growth rates for hVIVO PLC have been 21% over the past three years , 38% over the past five years , and 39% over the past ten years .

Back to Top